VAXON Biotech SA

Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. As per this reports findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. Report Highlights: The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer. The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers. Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries. Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells. Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry. Key Topics Covered: 1. Introduction to Peptide Cancer Vaccine 2. Need of Peptide Vaccines2.1 Why Peptides - More Desirable2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines3.1 On the Basis of Sources Obtained3.2 On the Basis of Length3.3 On the Basis of Epitopes 4. Mechanism of Action of Peptide Cancer Vaccines4.1 Immunological Cells Activated by Peptide Cancer Vaccines4.2 Procedure of Synthetic Peptide Vaccine Development 5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia5.1 Basic Layout of the Study5.2 Introduction to WT1 Peptide5.3 Methodologies Involved In the Clinical Study5.4 Results of the Clinical Trial Study 6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer6.1 Colorectal Cancer6.2 Lung Cancer6.3 Pancreatic Cancer6.4 Gastric Cancer6.5 Prostate Cancer6.6 Breast Cancer 7. Global Peptide Cancer Vaccine Market Overview 8. Global Peptide Cancer Vaccine Market Trends8.1 Optimized Cryptic Peptides8.2 Therapeutic CpG Peptide-Based Cancer Vaccine8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides8.4 Recombinant Peptide Vaccine8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines 9. Global Peptide Cancer Vaccine Pipeline Overview9.1 By Country9.2 By Company9.3 By Patient Segment9.4 By Phase 10. Global Peptide Cancer Vaccine Clinical Trials Insight10.1 Research10.2 Preclinical10.3 Phase-I10.4 Phase-I/II10.5 Phase-II10.6 Phase-III 11. LucaVax - First Commercially available Peptide Cancer Vaccine 12. Global Peptide Cancer Vaccine Market Dynamics12.1 Market Driving Factors12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development 13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy 14. Competitive Landscape14.1 Enzo Life Science (Alexis Biotech)14.2 Antigen Express14.3 BioLife Science14.4 Immatics Biotechnologies14.5 Immune Design14.6 Imugene14.7 Immunomedics14.8 ISA Pharmaceuticals14.9 Galena Biopharma14.10 Generex Biotechnology Corporation14.11 Lytix Biopharma14.12 Merck (Merck Serono)14.13 OncoTherapy Science14.14 Oncothyreon14.15 Pfizer14.16 Phylogica14.17 Symphogen (Receptor BioLogix)14.18 Sumitomo Dainippon Pharma14.19 TapImmune14.20 Vaxon Biotech For more information about this report visit

Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. As per this reports findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. Report Highlights: The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer. The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers. Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries. Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells. Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry. Key Topics Covered: 1. Introduction to Peptide Cancer Vaccine 2. Need of Peptide Vaccines2.1 Why Peptides - More Desirable2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines3.1 On the Basis of Sources Obtained3.2 On the Basis of Length3.3 On the Basis of Epitopes 4. Mechanism of Action of Peptide Cancer Vaccines4.1 Immunological Cells Activated by Peptide Cancer Vaccines4.2 Procedure of Synthetic Peptide Vaccine Development 5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia5.1 Basic Layout of the Study5.2 Introduction to WT1 Peptide5.3 Methodologies Involved In the Clinical Study5.4 Results of the Clinical Trial Study 6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer6.1 Colorectal Cancer6.2 Lung Cancer6.3 Pancreatic Cancer6.4 Gastric Cancer6.5 Prostate Cancer6.6 Breast Cancer 7. Global Peptide Cancer Vaccine Market Overview 8. Global Peptide Cancer Vaccine Market Trends8.1 Optimized Cryptic Peptides8.2 Therapeutic CpG Peptide-Based Cancer Vaccine8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides8.4 Recombinant Peptide Vaccine8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines 9. Global Peptide Cancer Vaccine Pipeline Overview9.1 By Country9.2 By Company9.3 By Patient Segment9.4 By Phase 10. Global Peptide Cancer Vaccine Clinical Trials Insight10.1 Research10.2 Preclinical10.3 Phase-I10.4 Phase-I/II10.5 Phase-II10.6 Phase-III 11. LucaVax - First Commercially available Peptide Cancer Vaccine 12. Global Peptide Cancer Vaccine Market Dynamics12.1 Market Driving Factors12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development 13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy 14. Competitive Landscape14.1 Enzo Life Science (Alexis Biotech)14.2 Antigen Express14.3 BioLife Science14.4 Immatics Biotechnologies14.5 Immune Design14.6 Imugene14.7 Immunomedics14.8 ISA Pharmaceuticals14.9 Galena Biopharma14.10 Generex Biotechnology Corporation14.11 Lytix Biopharma14.12 Merck (Merck Serono)14.13 OncoTherapy Science14.14 Oncothyreon14.15 Pfizer14.16 Phylogica14.17 Symphogen (Receptor BioLogix)14.18 Sumitomo Dainippon Pharma14.19 TapImmune14.20 Vaxon Biotech For more information about this report visit

May 11, 2015 By Alex Keown , BioSpace.com Breaking News Staff SUMMIT, N.J. -- Robert J. Hugin , chief executive officer of Celgene Corporation told Bloomberg News licensing deals with other pharmaceutical companies are paying off with eight new compounds the company plans to put into human testing over the next year-and-a-half. Hugin told Bloomberg the deal making strategy his company has become known for, is paying off. “We think the strategy is working very well. There’s great productivity coming out of the partnerships,” Hugin said to Bloomberg . In 2014 Celgene entered into 10 deals with other companies, shelling out an average of $222 million in upfront payments to its partners. Celgene ’s 2014 deal making was the most of any other biotech firm, Bloomberg said. However, Celgene has been striking profitable partnerships for years. Acceleron In 2008 Celgene entered into a $2 billion deal with Acceleron Pharma to develop and market Acceleron ‘s lead bone-forming protein, Sotatercept , formerly known as ACE-011. Sotatercept is an investigational protein therapeutic that increases red blood cell levels by targeting molecules in the TGF-ß superfamily for the treatment of anemia in rare blood diseases. The two companies are also collaborating on ACE-536, another blood treatment that targets sickle cell anemia. The drug is currently in late-stage trials. Agios In April Celgene entered into an $80 million agreement with Agios Pharmaceuticals, Inc. to develop AG-881, a small molecule that has shown in preclinical studies to fully penetrate the blood brain barrier and inhibit isocitrate dehydrogenase-1 (IDH1) and IDH2 mutant cancer models. The companies said they plan to initiate clinical development of AG-881 in the second quarter of 2015. That will make the third mutant inhibitor discovered by Agios to enter into clinical development. The two companies entered into a similar agreement in 2010 to develop Agios ’ other mutant inhibitor AG-221 and AG-120. Under that deal Agios is eligible for up to $240 million in milestone payments. Northern Biologics In addition to the Agios deal, Celgene also announced in April that it struck a $30 million agreement with one-year-old Canada-based Northern Biologics to advance that company’s work in oncology and fibrosis therapeutics. AstraZeneca PLC Also in April Celgene entered into a collaborative agreement with AstraZeneca that will allow the U.S.-based drug firm to develop MEDI4736, AstraZeneca ’s immunotherapy treatment for blood cancer. Under the deal, Celgene will be responsible for selling MEDI4736 in blood cancers and will pay AstraZeneca an initial royalty of 70 percent, which will decrease to approximately half of sales over a period of four years. Nogra Pharma Other noted deals include Celgene ’s Crohn’s Disease drug GED-0301 (mongersen), licensed from Nogra Pharma for $710 million with a promise of nearly $2 billion more in milestone payments. Celgene plans to move GED-0301 to Phase III trial. Quanticel Pharmaceuticals Another April deal was the $485 million transaction to acquire cancer drugmaking company Quanticel Pharmaceuticals , following a partnership established in 2011. That alliance allowed Quanticel to develop its single-cell platform for analysis of tumor cellular content and apply the platform to target discovery and the development of high-quality drug candidates. Others Celgene also has additional research and development deals with NantBioscience , Nogra , OncoMed Pharmaceuticals, Inc. , PharmAkea Therapeutics , Presage , Quanticel, Pharmaceuticals , Sanford Burnham Medical Research Institute , Sanofi , Sutro Biopharma , Tengion Inc. , Triphase , Vaxon Biotech and VentiRx Pharmaceuticals, Inc. Celgene ’s deal making strategy has been pleasing to shareholders, with stock up nearly 60 percent since last year. Celgene ’s stock had a morning high of $114.44 this morning, up from its open of $113.83. Celgene is valued at $97 billion and currently has seven approved drugs on the market, including the company’s top cancer drug, Revlimid, which brought in $4.98 billion last year. The base for Revlimid is thalidomide, a drug that garnered a bad reputation in the 1960s for causing birth defects. Celgene acquired the patent for thalidomide in 1992 and has transformed the drug’s reputation by adapting it for use as a therapy for the blood cancer multiple myeloma. In addition to Revlimid, Celgene also markets oncology drug Abraxane, which had firs quarter sales of $223 million. The company is seeking to market Abraxane in China as a treatment for pancreatic cancer. The drug has been approved to treat pancreatic cancer in other countries, but not China, Bloomberg reported.